Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings
Clinical Infectious Diseases · 16.09.2025 · 81 (2) · 372-378
DOI: 10.1093/cid/ciaf132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 22.03.2025. Verfasst von Isabel Cuella-Martin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. Hauptthemen laut MEDLINE: Rifampin, Mycobacterium tuberculosis, Drug Resistance, Bacterial, Antibiotics, Antitubercular. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ITM's SOFI program, Flemish Government, Science & Innovation, The Belgian Federal Public Service of Development Cooperation.
Abstract (Originalsprache)
Background
Xpert MTB/RIF Ultra (Ultra) aimed to improve the specificity in identifying rifampicin-resistant tuberculosis (RR-TB), compared to Xpert MTB/RIF.
Methods
In a nationwide study in Rwanda, patients diagnosed with RR-TB by Ultra between December 2021 and January 2024 underwent repeat Ultra testing, complemented by rpoB gene sequencing and phenotypic drug-susceptibility testing (pDST), serving as reference tests.
Results
Of 129 patients initially diagnosed with RR-TB by Ultra, only 41 (32%) had concordant rifampicin results upon repeat Ultra testing. The remaining 88 patients (68%) had unconfirmed resistance on repeat Ultra. Reference testing was available for 40 (98%) of 41 confirmed cases, all verified as true RR-TB. Among 88 unconfirmed cases, reference testing was available for 61 (69%), with 7 (11%) confirmed as true RR-TB, whereas 54 (89%) were found to have rifampicin-susceptible TB. Notably, 89% of 55 patients with very low bacillary loads on their initial Ultra had false RR-TB results, a significantly higher risk of false resistance compared to other bacillary load categories combined (risk ratio: 8.20; 95% confidence interval [CI]: 3.56–18.85; P < .001). Consequently, 53% (54/101) of initial RR patients with available reference testing received unnecessary RR-TB treatment.
Conclusions
Ultra represents a valuable tool for rapid RR-TB detection; however, in low prevalence settings its low positive predictive value for RR detection is largely driven by samples with very low bacillary loads. As programs expand active case-finding and early detection of asymptomatic disease, the proportion of TB detected with very low bacillary load will increase. Diagnostic algorithms require adjustments to prevent unnecessary RR-TB treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
- Department of Biomedical Sciences, Antwerp University, Antwerp, Belgium.
- National Reference Laboratory Division, Department of Biomedical Services, Rwanda Biomedical Centre, Kigali, Rwanda.
- Research Innovation and Data Science Division, Rwanda Biomedical Centre, Kigali, Rwanda.
- Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
- Mycobacterial Diseases and Neglected Tropical Diseases Unit, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
ORCID-Profile: Isabel Cuella-Martin, Aymen Ahmed, Docteur Runyambo, Jelle Keysers, Ellen M H Mitchell, Tom Decroo, Bouke C de Jong, Jean Claude Semuto Ngabonziza
Förderung
- ITM's SOFI program
- Flemish Government, Science & Innovation
- The Belgian Federal Public Service of Development Cooperation
- Research Foundation-Flanders
- Belgian Directorate General for Development Cooperation
- Research Foundation—Flanders
Zitieren
APA
Cuella-Martin, I., Hakizayezu, F., Ahmed, A., Runyambo, D., Niyompano, H., Keysers, J., De Rijk, W. B., Mulders, W., Mitchell, E. M. H., Decroo, T., Habimana, Y. M., Migambi, P., Muvunyi, C. M., de Jong, B. C., Rigouts, L., & Ngabonziza, J. C. S. (2025). Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings. Clinical Infectious Diseases, 81(2), 372-378. https://doi.org/10.1093/cid/ciaf132
Vancouver
Cuella-Martin I, Hakizayezu F, Ahmed A, Runyambo D, Niyompano H, Keysers J, et al. Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings. Clinical Infectious Diseases. 2025;81(2):372-378. doi:10.1093/cid/ciaf132
BibTeX
@article{CuellaMartin2025,
author = {Cuella-Martin, Isabel and Hakizayezu, Francois and Ahmed, Aymen and Runyambo, Docteur and Niyompano, Hosee and Keysers, Jelle and De Rijk, Willem Bram and Mulders, Wim and Mitchell, Ellen M H and Decroo, Tom and Habimana, Yves Mucyo and Migambi, Patrick and Muvunyi, Claude Mambo and de Jong, Bouke C and Rigouts, Leen and Ngabonziza, Jean Claude Semuto},
title = {Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {81},
number = {2},
pages = {372--378},
doi = {10.1093/cid/ciaf132}
}
EUVIMED